Back to search

Peptide record

TPDB42857

IDP-LLCb02 Anticancer standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42857
IDP-LLCb02
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 33-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA
Physicochemical Analysis
C189H311N55O43S1
DCGHT
K
4073.95
11.67
10
1
15
+9
5.58
-0.779
85.76
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
12490
306.58
7
Residue Composition
number
3
A
3
R
1
N
0
D
0
C
1
E
3
Q
0
G
0
H
2
I
3
L
7
K
1
M
1
F
1
P
2
S
0
T
2
W
1
Y
2
V
Amino Acid Distribution
A: 3 R: 3 N: 1 D: 0 C: 0 E: 1 Q: 3 G: 0 H: 0 I: 2 L: 3 K: 7 M: 1 F: 1 P: 1 S: 2 T: 0 W: 2 Y: 1 V: 2
Chemical Descriptors
33
C189H311N55O43S1
4073.95
11.67
+9
5.58
-0.779
Free
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

EC50
EC50 ~ 7.5 µM
Anticancer
7.5 µM

Target

Lung Cancer
NCl-H187
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

EC50
EC50 ~ 10 µM
Anticancer
10 µM

Target

Lung Cancer
NCl-H82
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1
Evidence 3 Activity

Activity

EC50
EC50 ~ 15 µM
Anticancer
15 µM

Target

Lung Cancer
NCl-H510A
Lung

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1